Enfusion Investor Presentation Deck

Long-term targets ARR growth Revenue growth Gross margin Adj. EBITDA margin •:enfusion 2020 37% 35% 73% 32% Long-term targets 30 - 35% 30 - 35% 77.5 - 80% 30-35% PROPRIETARY AND CONFIDENTIAL Ⓒ2021 ENFUSION. ALL RIGHTS RESERVED. 35

View entire presentation